Expert Interview
A Third Look: Discussing Hoth Therapeutics positive initial data in Phase 2a Clinical Trial CLEER-001, evaluating HT-001 for the treatment of Pruritus associated with skin toxicities caused by EGFR inhibitors
Ticker(s): HOTH- I see at least 20-40 patients per month for pruritus or acneiform rash.
- Yes I can speak on potential, in limited manner
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
